Metraipolis › archive › dc_40cc00c02004

The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight — Europe PMC PMID:42428556

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42428556
DOI
10.3389/jpps.2026.16610
License (as archived)
solo-consultazione
Archived
2026-10-19T04:00:25.065Z
SHA-256 of the archived text
7ec037c2e6ad407612f91381f024432abaefce961ae7679cfb80b52055d96922
Stable URL of this page
https://metraipolis.com/documento/dc_40cc00c02004

How to cite

The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight — Europe PMC PMID:42428556 — Europe PMC (en), https://europepmc.org/article/MED/42428556 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_40cc00c02004 (Metraipolis archive dc_40cc00c02004, sha256 7ec037c2e6ad407612f91381f024432abaefce961ae7679cfb80b52055d96922)
BibTeX
@misc{dc40cc00c02004,
  title = {The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight — Europe PMC PMID:42428556},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42428556},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_40cc00c02004; sha256 7ec037c2e6ad407612f91381f024432abaefce961ae7679cfb80b52055d96922},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42428556. Agents can read the archived copy with the MCP tool read_document.